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Introduction: The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more
frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB
recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy
analysis.
Materials and Methods: Multicentre, randomized, open-label, non-inferiority trial (non-inferiority margin 10%). Treatment
failure (TF) was defined as CVF (two consecutive HIV-RNA 50 cp/mL) or discontinuation for any cause. In the monotherapy
arm, patients with CVF re-introduced their previous NRTIs and remained in the study if HIV-RNA B50 copies/mL within 12
weeks of re-intensification.
Results: 101 patients evaluated (Figure 1): 85% males, 21% HCV-positive, median (IQR) age of 42 (3648) years, baseline CD4
576 (447743) cells/mL. In the 96-week analysis (ITT; TFfailure), efficacy was 64% (32/50) in the monotherapy arm and 63%
(32/51) in the triple-therapy arm (difference 1.3%, 95% CI 17.520.1). Fourteen patients in monotherapy and two in triple-
therapy arm had CVF; median HIV-RNA was 136 (72376) copies/mL. In monotherapy arm, no PI or NRTI associated resistance
mutations were observed at CVF. All patients who re-intensified re-suppressed. In monotherapy arm, TF was more frequent in
HCV-co-infected patients (64% vs 28%; p0.041). In the secondary analysis (ITT; re-intensificationsuccess), 82% (41/50) in
monotherapy arm and 63% (32/51) in triple-therapy arm were on study at week 96 (difference 19.3%, 95% CI 2.236.3). SAEs
occurred in four (8%) patients in the monotherapy arm (one left basal pneumonia, one acute coronary stenosis, one traumatic
lesion, one nephrolithiasis) and two (4%) in the triple therapy arm (one sepsis, one renal failure). Drug-related adverse events
(AEs) leading to discontinuation were three (6%) in the monotherapy arm (two AEs occurred in patients after successful re-
intensification) and 12 (23.5%) in the triple-therapy (p0.023).
Conclusions: Despite the small sample size, the primary 96-week analysis showed that simplification to ATV/r monotherapy
showed inferior efficacy to maintaining ATV/r triple-therapy but appeared to be superior when re-intensification was considered
success.
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Figure 1. The MODAT trial: 96-week patients disposition.
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